Communique from annual general meeting in Senzime AB (publ)

Annual report and results

The annual general meeting adopted the income statement and the balance sheet for the financial year 2019 and resolved, in accordance with the board of directors’ proposal, that the result according to the approved income statement should be transferred to a new account. No dividends are be paid.

Discharge from liability

The general meeting granted the members of the board of directors and the managing director discharge from liability for the management of the company’s business for the financial year 2019.

Remuneration to the board of directors and the auditor

The annual general meeting resolved that the chairman shall receive remuneration with SEK 100,000 and that every other board member shall receive remuneration with SEK 50,000. Furthermore, it was resolved that no remuneration shall be paid to a board member who during 2020 has received payments from the Company for consulting services exceeding twice the remuneration amount.

The annual general meeting resolved that the auditor shall receive remuneration according to approved invoice.

Election of board of directors and auditor

The annual general meeting resolved that the board of directors shall consist of four (4) directors without any deputy directors.

The general meeting resolved, for the time until the end of the next annual general meeting, to re-elect Adam Dahlberg, Philip Siberg, Sorin Brull and Lennart Kalén as members of the board of directors. Philip Siberg was elected as the chairman of the board of directors.

It was resolved to re-elect PricewaterhouseCoopers AB as auditor, with Leonard Daun as chief auditor, for the time until the end of the next annual general meeting.

Nomination committee for the annual general meeting 2020

The annual general meeting resolved that the Company, in advance of the annual general meeting in 2021, shall establish a nomination committee. It was resolved that the members of the nomination committee shall be appointed by instruction from the chairman of the board of directors to the three largest shareholders in the Company on 1 September 2020 to appoint a representative each that, together with the chairman of the board of directors, shall constitute the nomination committee

Adoption of new articles of association

The annual general meeting resolved to amend the wording of the provisions in the articles of association in accordance with the following.

§ 3 Objectives of the company

The company’s objective is to carry out development, manufacturing and sales of medical technology equipment and other business compatible therewith.

§ 7 Notice

Notice to attend an ordinary general meeting or an extraordinary general meeting where an amendment of the articles of association shall be addressed, shall be issued no earlier than six (6) and no later than four (4) weeks prior to the general meeting. Notice to attend other extraordinary general meetings shall be issued no earlier than six (6) and no later than two (2) weeks prior to the general meeting. Notice to attend a general meeting shall be announced in The Official Swedish Gazette (Sw. Post- och Inrikes Tidningar) and on the company’s website. The fact that notice has been issued shall be announced in Dagens Nyheter.

Shareholders who wish to participate at a general meeting shall, in addition to requirements for participation set out in the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)), also notify the company thereof no later than on the date stated in the notice to attend the general meeting. Such a date may not be a Sunday, other public holiday, Saturday, Midsummer Eve, Christmas Eve or New Year's Eve and may not occur earlier than the fifth weekday prior to the general meeting.

Shareholders may be accompanied by one or two advisors at a general meeting provided that the shareholder has given the company notice of the number of advisors in the manner stated in the previous paragraph.

§ 10 CSD clause

The company’s shares shall be registered in a central securities depository register pursuant to the Financial Instruments Accounts Act (Sw. lagen (1998:1479) om värdepapperscentraler och kontoföring av finansiella instrument).

The resolution was supported by shareholders holding more than two thirds of the votes cast and the shares represented at the general meeting.

The proposal regarding an issue of warrants with deviation from the shareholders’ pre-emption rights

The board of directors announced that it had resolved to withdraw its proposal. The reason for the withdrawal is that the board of directors wishes to prepare an amended proposal for the introduction of an incentive program in dialogue with institutional investors.

The proposal regarding an employee stock option program

The board of directors announced that it had resolved to withdraw its proposal. The reason for withdrawal is that the board of directors wishes to prepare an amended proposal for the introduction of an employee stock option program in dialogue with institutional investors.

Authorization to the board of directors to resolve on new issues

The annual general meeting authorized the board of directors to, one or several occasions for the time until the next annual general meeting, increase the Company’s share capital with not more than ten (10) percent of the Company’s at each time registered share capital through an issue of shares, warrants and/or convertible instruments, with or without deviation from the shareholders’ pre-emption rights and/or by an issue in kind or by way of set-off. An issue in accordance with the authorization shall be made at fair market value.

The resolution was supported by shareholders holding more than two thirds of the votes cast and the shares represented at the general meeting.

All resolutions at the annual general meeting were adopted unanimously.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB

Tel: +46 708-13 34 17, e-mail: pia.renaudin@senzime.com

————————————

Senzime AB (publ)

The board of directors

About Senzime

Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com